{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:50:24Z","timestamp":1789588224237,"version":"build-2803163510"},"reference-count":49,"publisher":"Scientific Scholar","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Dermatol Venereol Leprol"],"published-print":{"date-parts":[[2012]]},"DOI":"10.4103\/0378-6323.102354","type":"journal-article","created":{"date-parts":[[2012,10,13]],"date-time":"2012-10-13T11:24:23Z","timestamp":1350127463000},"page":"671","source":"Crossref","is-referenced-by-count":23,"title":["Rituximab in pemphigus"],"prefix":"10.25259","volume":"78","author":[{"given":"AmrinderJ","family":"Kanwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshavamurthy","family":"Vinay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","reference":[{"key":"key-10.4103\/0378-6323.102354-1","first-page":"21","volume-title":"Pemphigus in North India","author":"Kanwar","year":"2006","journal-title":"J Cutan Med Surg"},{"key":"key-10.4103\/0378-6323.102354-2","first-page":"5","volume-title":"Pemphigus in India.A note","author":"Sehgal","year":"1972","journal-title":"Indian J Dermatol","ISSN":"https:\/\/id.crossref.org\/issn\/0019-5154","issn-type":"print"},{"key":"key-10.4103\/0378-6323.102354-3","first-page":"349","volume-title":"Incidence of pemphigus in Thrissur district, south India","author":"Kumar","year":"2008","journal-title":"Indian J Dermatol Venereol Leprol","ISSN":"https:\/\/id.crossref.org\/issn\/0378-6323","issn-type":"print"},{"key":"key-10.4103\/0378-6323.102354-4","first-page":"1236","volume-title":"Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975","author":"Lever","year":"1977","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/0378-6323.102354-5","first-page":"199","volume-title":"Pulse therapy with dexamethasone-cyclophosphamide in pemphigus","author":"Pasricha","year":"1984","journal-title":"Indian J Dermatol Venereol Leprol","ISSN":"https:\/\/id.crossref.org\/issn\/0378-6323","issn-type":"print"},{"key":"key-10.4103\/0378-6323.102354-6","first-page":"371","volume-title":"Dexamethasone-cyclophosphamide pulse therapy in pemphigus","author":"Kaur","year":"1990","journal-title":"Int J Dermatol"},{"key":"key-10.4103\/0378-6323.102354-7","first-page":"439","volume-title":"Pemphigus in India","author":"Kanwar","year":"2011","journal-title":"Indian J Dermatol Venereol Leprol","ISSN":"https:\/\/id.crossref.org\/issn\/0378-6323","issn-type":"print"},{"key":"key-10.4103\/0378-6323.102354-8","first-page":"203","volume-title":"The adjuvant therapy of pemphigus.An update","author":"Bystryn","year":"1996","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/0378-6323.102354-9","first-page":"1121","volume-title":"Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes","author":"Bubien","year":"1993","journal-title":"J Cell Biol"},{"key":"key-10.4103\/0378-6323.102354-10","first-page":"435","volume-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"key-10.4103\/0378-6323.102354-11","first-page":"1644","volume-title":"Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies","author":"Shan","year":"1998","journal-title":"Blood"},{"key":"key-10.4103\/0378-6323.102354-12","first-page":"564","volume-title":"B cells move to centre stage: novel opportunities for autoimmune disease treatment","author":"Browning","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"key-10.4103\/0378-6323.102354-13","first-page":"142","volume-title":"Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL","author":"Heizmann","year":"2001","journal-title":"Am J Hematol"},{"key":"key-10.4103\/0378-6323.102354-14","first-page":"785","volume-title":"Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder","author":"Salopek","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0378-6323.102354-15","first-page":"899","volume-title":"Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab","author":"Goebeler","year":"2003","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0378-6323.102354-16","first-page":"366","volume-title":"Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases","author":"Hertl","year":"2008","journal-title":"J Dtsch Dermatol Ges"},{"key":"key-10.4103\/0378-6323.102354-17","first-page":"56","volume-title":"Rituximab in treatment-resistant autoimmune blistering skin disorders","author":"Schmidt","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"key-10.4103\/0378-6323.102354-18","first-page":"734","volume-title":"Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: A case series of 9 patients","author":"Matsukura","year":"2012","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/0378-6323.102354-19","doi-asserted-by":"crossref","unstructured":"Kanwar AJ, Tsuruta D, Vinay K, Koga H, Ishii N, Dainichi T, et al. Efficacy and safety of rituximab treatment in Indian pemphigus patients. J Eur Acad Dermatol Venereol 2011. [In Press].","DOI":"10.1111\/j.1468-3083.2011.04391.x"},{"key":"key-10.4103\/0378-6323.102354-20","doi-asserted-by":"crossref","unstructured":"Reguiai Z, Tabary T, Maizieres M, Bernard P . Rituximab treatment of severe pemphigus: Long-term results including immunologic follow-up. J Am Acad Dermatol 2012. [In Press].","DOI":"10.1016\/j.jaad.2011.12.019"},{"key":"key-10.4103\/0378-6323.102354-21","first-page":"1064","volume-title":"Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris","author":"Craythorne","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0378-6323.102354-22","first-page":"683","volume-title":"Rituximab in severe pemphigus","author":"Schmidt","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"key-10.4103\/0378-6323.102354-23","first-page":"909","volume-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key-10.4103\/0378-6323.102354-24","first-page":"172","volume-title":"Generalized erythrodermic pemphigus foliaceus in a child and its successful response to rituximab treatment","author":"Connelly","year":"2007","journal-title":"Pediatr Dermatol"},{"key":"key-10.4103\/0378-6323.102354-25","first-page":"461","volume-title":"Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab)","author":"Kong","year":"2005","journal-title":"Pediatr Dermatol"},{"key":"key-10.4103\/0378-6323.102354-26","first-page":"449","volume-title":"Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab","author":"Schmidt","year":"2005","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0378-6323.102354-27","first-page":"13","volume-title":"Rituximab in childhood pemphigus vulgaris: A long-term follow-up case and review of the literature","author":"Fuertes","year":"2010","journal-title":"Dermatology"},{"key":"key-10.4103\/0378-6323.102354-28","first-page":"1499","volume-title":"Pregnancy outcomes after maternal exposure to rituximab","author":"Chakravarty","year":"2011","journal-title":"Blood"},{"key":"key-10.4103\/0378-6323.102354-29","first-page":"545","volume-title":"A single cycle of rituximab for the treatment of severe pemphigus","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0378-6323.102354-30","first-page":"1033","volume-title":"Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature","author":"Cianchini","year":"2007","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/0378-6323.102354-31","first-page":"990","volume-title":"Rituximab in the adjuvant treatment of pemphigus vulgaris: A prospective open-label pilot study in five patients","author":"Goh","year":"2007","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0378-6323.102354-32","doi-asserted-by":"crossref","unstructured":"Cianchini G, Lupi F, Masini C, Corona R, Puddu P, De Pit\u00e0 O.Therapy with rituximab for autoimmune pemphigus: Results from a single-center observational study on 42 cases with long-term follow-up. J Am Acad Dermatol 2012. [In Press].","DOI":"10.1016\/j.jaad.2011.11.007"},{"key":"key-10.4103\/0378-6323.102354-33","first-page":"1772","volume-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0378-6323.102354-34","first-page":"154","volume-title":"Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine\/mycophenolate mofetil: a pilot study of 23 patients","author":"Kasperkiewicz","year":"2012","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0378-6323.102354-35","first-page":"511","volume-title":"Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy","author":"Feldman","year":"2012","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0378-6323.102354-36","first-page":"R75","volume-title":"Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: Experience from a national registry (GRAID)","author":"Tony","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"key-10.4103\/0378-6323.102354-37","first-page":"552","volume-title":"Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients","author":"Kasperkiewicz","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/0378-6323.102354-38","first-page":"405","volume-title":"Low dose rituximab is effective in pemphigus","author":"Horvath","year":"2012","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0378-6323.102354-39","first-page":"493","volume-title":"IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group","author":"Feuring-Buske","year":"2000","journal-title":"Ann Hematol"},{"key":"key-10.4103\/0378-6323.102354-40","first-page":"284","volume-title":"Rituximab-induced vasculitis: A case report and review of the medical published work","author":"Kim","year":"2009","journal-title":"J Dermatol"},{"key":"key-10.4103\/0378-6323.102354-41","first-page":"377","volume-title":"Toxic epidermal necrolysis in two rhesus macaques (Macaca mulatta) after administration of rituximab","author":"Allen","year":"2005","journal-title":"Comp Med"},{"key":"key-10.4103\/0378-6323.102354-42","first-page":"1948","volume-title":"Stevens-Johnson syndrome after treatment with rituximab","author":"Lowndes","year":"2002","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0378-6323.102354-43","first-page":"243","volume-title":"A mechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease: Part 2","author":"Bremmer","year":"2009","journal-title":"Dermatitis"},{"key":"key-10.4103\/0378-6323.102354-44","first-page":"169","volume-title":"Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia","author":"Herold","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"key-10.4103\/0378-6323.102354-45","first-page":"136","volume-title":"Progressive multifocal leukoencephalopathy in a HIV-negative patient with small lymphocytic leukemia following Treatment with Rituximab","author":"Chakraborty","year":"2011","journal-title":"Case Rep Oncol"},{"key":"key-10.4103\/0378-6323.102354-46","first-page":"558","volume-title":"Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials","author":"van","year":"2010","journal-title":"J Rheumatol"},{"key":"key-10.4103\/0378-6323.102354-47","first-page":"456","volume-title":"Tolerability and safety of rituximab (MabThera)","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"key-10.4103\/0378-6323.102354-48","first-page":"3896","volume-title":"Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis","author":"Keystone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"key-10.4103\/0378-6323.102354-49","first-page":"228","volume-title":"Long-term efficacy of dexamethasone-cyclophosphamide pulse therapy in pemphigus","author":"Kanwar","year":"2002","journal-title":"Dermatology"}],"container-title":["Indian Journal of Dermatology, Venereology, and Leprology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T00:42:55Z","timestamp":1612658575000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijdvl.com\/rituximab-in-pemphigus\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"alternative-id":["102354"],"URL":"https:\/\/doi.org\/10.4103\/0378-6323.102354","relation":{},"ISSN":["0378-6323"],"issn-type":[{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2012]]}}}